Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Murphy

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Medicinal Chemistry|March 14, 2024
Discovery and Characterization of a New Class of C5aR1 Antagonists Showing <i>In Vivo</i> ActivityFrancis Hubler, Dorte Renneberg, Hervé Siendt, et al.
Hepatology (Baltimore, Md.)|September 18, 2008
C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasiaWilliam E Blanco-Bose, Mark J Murphy, Armin Ehninger, et al.
British Journal of Pharmacology|March 29, 2025
Efficacy of IDOR-1117-2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitisPaulina Kulig, Pijus Brazauskas, Madeleine Suffiotti, et al.
Genes & Development|November 17, 2004
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiationAnne Wilson, Mark J Murphy, Thordur Oskarsson, et al.
The Lancet. Rheumatology|November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trialAnca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
Arthritis Research & Therapy|November 29, 2021
Cenerimod, a selective S1P<sub>1</sub> receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndromeEstelle Gerossier, Saba Nayar, Sylvie Froidevaux, et al.
Journal of Medicinal Chemistry|March 8, 2023
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory PathologiesEmmanuel A Meyer, Päivi Äänismaa, Eric A Ertel, et al.
Kidney International|January 23, 2025
The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndromeKate Smith-Jackson, Patrick Walsh, Wioleta M Zelek, et al.
Journal of Medicinal Chemistry|May 10, 2024
Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune DiseasesEmmanuel A Meyer, Andrew L Croxford, Carmela Gnerre, et al.
RMD Open|September 12, 2020
Preclinical to clinical translation of cenerimod, a novel S1P<sub>1</sub> receptor modulator, in systemic lupus erythematosusDaniel S Strasser, Sylvie Froidevaux, Virginie Sippel, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Medicinal Chemistry|March 14, 2024
Discovery and Characterization of a New Class of C5aR1 Antagonists Showing <i>In Vivo</i> ActivityFrancis Hubler, Dorte Renneberg, Hervé Siendt, et al.
Hepatology (Baltimore, Md.)|September 18, 2008
C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasiaWilliam E Blanco-Bose, Mark J Murphy, Armin Ehninger, et al.
British Journal of Pharmacology|March 29, 2025
Efficacy of IDOR-1117-2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitisPaulina Kulig, Pijus Brazauskas, Madeleine Suffiotti, et al.
Genes & Development|November 17, 2004
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiationAnne Wilson, Mark J Murphy, Thordur Oskarsson, et al.
The Lancet. Rheumatology|November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trialAnca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
Arthritis Research & Therapy|November 29, 2021
Cenerimod, a selective S1P<sub>1</sub> receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndromeEstelle Gerossier, Saba Nayar, Sylvie Froidevaux, et al.
Journal of Medicinal Chemistry|March 8, 2023
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory PathologiesEmmanuel A Meyer, Päivi Äänismaa, Eric A Ertel, et al.
Kidney International|January 23, 2025
The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndromeKate Smith-Jackson, Patrick Walsh, Wioleta M Zelek, et al.
Journal of Medicinal Chemistry|May 10, 2024
Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune DiseasesEmmanuel A Meyer, Andrew L Croxford, Carmela Gnerre, et al.
RMD Open|September 12, 2020
Preclinical to clinical translation of cenerimod, a novel S1P<sub>1</sub> receptor modulator, in systemic lupus erythematosusDaniel S Strasser, Sylvie Froidevaux, Virginie Sippel, et al.
Pageof 2